Can Crucell deliver for J&J?; Medicago gets FDA OK for H1N1 study;

> With Dutch biotech Crucell about to be gobbled up by U.S. giant Johnson & Johnson, its chief executive Ronald Brus will need to deliver new vaccines quickly to make a success of the acquisition. Report

> Medicago has received FDA clearance for its Phase I H1N1 influenza VLP vaccine candidate clinical trial in the U.S. Medicago release

> Inovio Pharmaceuticals' new generation DNA vaccine delivery technology, which provides the powerful enabling capabilities of electroporation without contacting the skin, is highlighted in a paper published in the scientific journal Human Vaccines. Inovio release

Vaccine Market

> The BCG Vaccine Laboratory in Chennai, one of India's oldest vaccine manufacturing units, could soon become just a central drug testing lab. The Union health ministry had cancelled the manufacturing license of the company, housed in more than a century-old heritage building, Jan. 15, 2008, because it did not conform to the World Health Organization's good manufacturing protocol. News 

> Pevion Biotech today announced the appointment of Didier Hoch as Chairman of its Board of Directors. Until recently, Dr Hoch was President of Sanofi-Pasteur MSD, where he played a pivotal role in launching innovative vaccines, such as Gardasil, in Europe. Pevion release

> Vical has reported financial results for the year ended December 31, 2010. Vical had cash and investments of approximately $61 million at year-end 2010. The company received approximately $37 million of net proceeds from the sale of equity securities during 2010. Vical release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.